Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer

Author:

Matsumoto Toshihiko1,Cho Sien2,Nakasya Akio2,Nagai Hiroki2,Satake Hironaga2,Yasui Hisateru2

Affiliation:

1. Ichinoimiya nishi hospital

2. Kobe City Medical Center General Hospital

Abstract

Abstract

Purpose: To report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. Methods: We retrospectively collected real-world data from patients with colorectal and gastric cancer with cachexia who received anamorelin. Efficacy was assessed based on appetite improvement and body weight (BW) gain. Results: Forty-three patients with cancer and cachexia received anamorelin between June 2021 and October 2022 (23 with gastric cancer, 20 with colorectal cancer). The median observation time was 7.3 months, 25 patients were male, the median age was 71 years, the median body mass index was 19.7, and the ECOG PS 0/1/2 ratio was 4/33/6. Seven patients received best supportive care only, and 36 received concomitant chemotherapy with anamorelin. Thirty-four patients received prior chemotherapy with two or fewer regimens, while nine received three or more regimens. The median anamorelin treatment duration was 2.8 months, and overall survival (OS) from the first anamorelin administration was 7.3 months. Twenty-four and 21 patients experienced appetite improvement and BW gain, respectively, at 3 weeks, as did 20 and 15 at 12 weeks, respectively. In the multivariate analysis, anamorelin administration before second-line chemotherapy and colorectal cancer correlated with appetite improvement and BW gain after 3 weeks. Furthermore, anamorelin administration before second-line chemotherapy correlated with BW gain after 12 weeks in the univariate analysis, and OS significantly improved in patients with BW gain after 12 weeks. Conclusion: Early anamorelin contributes to appetite improvement and BW gain in colorectal and gastric cancer with cachexia.

Publisher

Research Square Platform LLC

Reference30 articles.

1. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia;Acharyya S;Cancer Cell,2005

2. Cancer cachexia: understanding the molecular basis;Argilés JM;Nat Rev Cancer,2014

3. Blum D, Omlin A, Fearon K, et al (2010) Evolving classification systems for cancer cachexia: ready for

4. clinical practice? Support Care Cancer 18:273–279.

5. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group;Dewys WD;Am J Med Eastern Cooperative Oncology Group,1980

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3